These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11286732)

  • 1. TB vaccines: progress and problems.
    Andersen P
    Trends Immunol; 2001 Mar; 22(3):160-8. PubMed ID: 11286732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?
    Moliva JI; Turner J; Torrelles JB
    Vaccine; 2015 Sep; 33(39):5035-41. PubMed ID: 26319069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis vaccine: A journey from BCG to present.
    Fatima S; Kumari A; Das G; Dwivedi VP
    Life Sci; 2020 Jul; 252():117594. PubMed ID: 32305522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical research concepts in tuberculosis vaccine development.
    Delogu G; Manganelli R; Brennan MJ
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():59-65. PubMed ID: 24283256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Vaccines Based on Bacille Calmette-Guérin.
    Nieuwenhuizen NE; Kaufmann SHE
    Front Immunol; 2018; 9():121. PubMed ID: 29459859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hunt for new tuberculosis vaccines: anti-TB immunity and rational design of vaccines.
    Xing Z
    Curr Pharm Des; 2001 Jul; 7(11):1015-37. PubMed ID: 11472252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.
    Huygen K; Content J; Denis O; Montgomery DL; Yawman AM; Deck RR; DeWitt CM; Orme IM; Baldwin S; D'Souza C; Drowart A; Lozes E; Vandenbussche P; Van Vooren JP; Liu MA; Ulmer JB
    Nat Med; 1996 Aug; 2(8):893-8. PubMed ID: 8705859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of BCG vaccine: a double-edged sword.
    Singh VK; Srivastava R; Srivastava BS
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):535-43. PubMed ID: 26810060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel TB vaccine; towards a strategy based on our understanding of BCG failure.
    Agger EM; Andersen P
    Vaccine; 2002 Nov; 21(1-2):7-14. PubMed ID: 12443657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects.
    Vilaplana C; Cardona PJ
    Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):373-377. PubMed ID: 30594319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG.
    Dietrich G; Viret JF; Hess J
    Int J Med Microbiol; 2003 Feb; 292(7-8):441-51. PubMed ID: 12635927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.
    Dai FY; Wang JF; Gong XL; Bao L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous Boost Following
    Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
    Front Immunol; 2018; 9():2439. PubMed ID: 30425711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium tuberculosis infection and vaccine development.
    Tang J; Yam WC; Chen Z
    Tuberculosis (Edinb); 2016 May; 98():30-41. PubMed ID: 27156616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.
    Lin MY; Geluk A; Smith SG; Stewart AL; Friggen AH; Franken KL; Verduyn MJ; van Meijgaarden KE; Voskuil MI; Dockrell HM; Huygen K; Ottenhoff TH; Klein MR
    Infect Immun; 2007 Jul; 75(7):3523-30. PubMed ID: 17502400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?
    Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S
    Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.